Medicine composition for preventing and treating diabetes mellitus and its use

A drug complex and diabetes technology, applied in the field of drug complexes for the prevention and treatment of type I diabetes, and peptides for the treatment of type I diabetes, can solve the problem that successful experiments are difficult to repeat, short expression time, no physiological regulation of blood sugar levels, etc. problems, to control autoimmunity, promote proliferation and function, and promote improvement

Active Publication Date: 2007-03-28
KUNMING INNOGEN PHARM TECH CO LTD +1
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There may be many negative effects in terms of clinical application, such as the introduction of genes into transplanted islets will be limited by the anti-islet immune response and the relatively short expression time of some plasmids
In addition, insulin or insulin analogues have been delivered to the liver, muscle, and other tissues by gene therapy, but the desired physiological regulation of blood glucose levels has not been achieved
Alternative therapies involve the in vivo delivery of genes such as PDX-1 to induce hepatocytes to differentiate into islet cells, but initial successful experiments have been difficult to replicate
In recent years, many gene-based therapies have indeed been proposed, but almost all of these therapies are based on viral vector gene transfer, have many limitations such as pathogenicity and immunogenicity, and none of them can be applied to humans

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for preventing and treating diabetes mellitus and its use
  • Medicine composition for preventing and treating diabetes mellitus and its use
  • Medicine composition for preventing and treating diabetes mellitus and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0040] In vivo experiments in animal models of diabetes : In vivo experiments were performed with 4-week-old female db / db model mice (BKS.Cg-m+ / +Leprdb, lot number 000642) from Jackson Laboratories (Bar Harbor, ME, USA) from Charles River Canada (Montreal, QC, Canada) C57BLKS / J mice and CD1 mice were used as controls. Female NOD mice were purchased from Taconic Farms (Germantown, NY). The rats tested were kept under the conditions of controlled light (12hs / 12hs), constant temperature, and no pathogenic bacteria, and sufficient food and drinking water suitable for rodents were provided. NOD mice were fed regular sterile Charles River #5075 chow. Daily injection of low doses of STZ (55mg / kg, i.p.) for 5 consecutive days induced insulin secretion-deficient diabetic mice.

[0041] Diabetes Diabetes Diabetes: The blood glucose levels of the rats were tested weekly with AccuSoft AdvantageTM tester or blood glucose meter (Roche Diagnostics). Diabetes is diagnosed when the blood g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a medicine composition for preventing and curing diabetes type I and its application. Said medicine composition includes (1), polypeptide capable of curing diabetes type I and (2), nucleic acid vaccine possesses the polypeptide which has 50% of homology respectively with proinsulin, GAD65 and B7-1 wa polypeptide which can be combined with T cell negative regulator CTLA-4. The invented medicine composition can effectively prevent and cure diabetes type I.

Description

technical field [0001] The invention relates to a drug compound for preventing and treating type I diabetes and its application. Specifically, the present invention relates to a polypeptide comprising 1) a polypeptide capable of treating type I diabetes; 2) comprising at least 50% homology to proinsulin, GAD65, and a B7-1wa polypeptide that can bind to T cell negative regulatory protein CTLA-4 A drug compound of a nucleic acid vaccine of a specific polypeptide for the prevention and treatment of type I diabetes, and its application. Background technique [0002] Diabetes is one of the main causes of human death and seriously endangers human health. Type I diabetes and type II diabetes are the two main forms of diabetes. Apoptosis, or programmed death, is the main cause of islet cell death in type I and type II diabetes. Both type I and type II diabetics exhibit progressive islet B-cell mass loss and decreased B-cell function. [0003] Glucagon-like peptide (GLP-1, amino ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K48/00A61P3/10
Inventor 王庆华黄晓航
Owner KUNMING INNOGEN PHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products